RSCM
IMNM icon

Rock Springs Capital Management’s Immunome IMNM Stock Holding History

Rock Springs Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.37M Hold
347,666
– – 0.36% 63
2026
Q1 		$7.6M Hold
347,666
– – 0.45% 55
2025
Q4 		$7.47M Buy
+347,666
New +$6.1M 0.38% 59

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Rock Springs Capital Management's IMNM Position: Q2 2026 in Review

Rock Springs Capital Management held its Immunome (IMNM) position steady in Q2 2026 at 347,666 shares worth $7.37M. The position accounts for 0.36% of the portfolio, ranked #63.

Rock Springs Capital Management first reported a position in IMNM in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.6M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Rock Springs Capital Management held 347,666 shares of Immunome worth $7.37M as of Q2 2026.
  • Rock Springs Capital Management left its Immunome share count unchanged in Q2 2026.
  • Immunome made up 0.36% of Rock Springs Capital Management's portfolio in Q2 2026, its #63 holding.
  • Rock Springs Capital Management first reported a position in Immunome in Q4 2025 and has held it in 3 quarters since.
  • Rock Springs Capital Management's Immunome position peaked at $7.6M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.